سعر ابيتويد apetoid‏ 100 مجم 3 اقراص 2026

immunosuppressive agent.antirheumatic antiviral agent.pyrimidine synthesis inhibitor

• Most common (>=10%): diarrhoea, elevated liver enzymes (ALT/AST), alopecia and rash.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Pregnancy (may cause fetal harm); severe hepatic impairment; known hypersensitivity to leflunomide or components; concomitant teriflunomide.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: embryo-fetal toxicity - exclude pregnancy before starting, use effective contraception, and use an accelerated drug-elimination procedure (cholestyramine or activated charcoal) if pregnancy occurs or is planned.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: severe liver injury including fatal liver failure; not recommended with pre-existing liver disease or ALT >2x ULN; stop if ALT >3x ULN and start elimination.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Immunosuppression, bone marrow suppression and serious infections (including tuberculosis), Stevens-Johnson syndrome/TEN/DRESS, peripheral neuropathy, interstitial lung disease and blood pressure increase may occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• TeriflunomideConcomitant use contraindicated.DailyMed (U.S. National Library of Medicine)
• Cholestyramine / activated charcoalRapidly decrease plasma teriflunomide; used for the elimination procedure.DailyMed (U.S. National Library of Medicine)
• Hepatotoxic or immunosuppressive drugs (e.g. methotrexate)Increased risk of hepatotoxicity / bone marrow toxicity; monitor more closely.DailyMed (U.S. National Library of Medicine)

• Contraindicated in pregnant women because of potential fetal harm; teratogenicity and embryolethality seen in animals at doses below or equivalent to human exposure.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Breastfeeding is not recommended during treatment because of the potential for serious adverse reactions in the infant.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Leflunomide: Isoxazole immunomodulatory agent that inhibits dihydroorotate dehydrogenase (mitochondrial enzyme of de novo pyrimidine synthesis) and has antiproliferative activity; essentially all in vivo activity is due to its active metabolite teriflunomide.